This issue of PET Clinics focuses on Radiotracers, and is edited by Drs. Neil Vasdev and Abass Alavi. Articles will include: PET/CT detection of HER2-positive metastases in patients with 89Zr-DFO-trastuzumab; uPAR-PET with 68Ga-NOTA-AE105: first clinical experience with a novel PET ligand; 64Cu-FBP8: A fibrin-targeted probe for imaging of thrombus; Imaging of synaptic density in the brain via synaptic vesicle glycoprotein 2A (SV2A) with a novel biomarker [11C]UCB-J; Neuroimaging of stress sensitive and neuroinflammatory targets in mood disorders; Impact of MR-based PET motion correction on the quantification of PET kinetic parameters in simultaneous cardiac PET-MR; Multimodal studies of the contributions of amyloid and tau burden to neurodegeneration in AD, FTD and Non-AD tauopathies; Imaging of prostate-specific membrane antigen (PSMA) using [18F]DCFPyL; Ga-68 GRPR antagonist imaging; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. viii 7. CME Accreditation Page - p. ix 8. Preface - p. xi 9. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis - p. 269 10. Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL - p. 289 11. Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology - p. 297 12. Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand - p. 311 13. Magnetic Resonance–based Motion Correction for Quantitative PET in Simultaneous PET-MR Imaging - p. 321 14. PET Imaging for Early Detection of Alzheimer’s Disease: From Pathologic to Physiologic Biomarkers - p. 329 15. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias - p. 351 16. Novel Phenotypes Detectable with PET in Mood Disorders: Elevated Monoamine Oxidase A and Translocator Protein Level - p. 361
This issue of PET Clinics focuses on Radiotracers, and is edited by Drs. Neil Vasdev and Abass Alavi. Articles will include: PET/CT detection of HER2-positive metastases in patients with 89Zr-DFO-trastuzumab; uPAR-PET with 68Ga-NOTA-AE105: first clinical experience with a novel PET ligand; 64Cu-FBP8: A fibrin-targeted probe for imaging of thrombus; Imaging of synaptic density in the brain via synaptic vesicle glycoprotein 2A (SV2A) with a novel biomarker [11C]UCB-J; Neuroimaging of stress sensitive and neuroinflammatory targets in mood disorders; Impact of MR-based PET motion correction on the quantification of PET kinetic parameters in simultaneous cardiac PET-MR; Multimodal studies of the contributions of amyloid and tau burden to neurodegeneration in AD, FTD and Non-AD tauopathies; Imaging of prostate-specific membrane antigen (PSMA) using [18F]DCFPyL; Ga-68 GRPR antagonist imaging; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. viii 7. CME Accreditation Page - p. ix 8. Preface - p. xi 9. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis - p. 269 10. Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL - p. 289 11. Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology - p. 297 12. Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand - p. 311 13. Magnetic Resonance–based Motion Correction for Quantitative PET in Simultaneous PET-MR Imaging - p. 321 14. PET Imaging for Early Detection of Alzheimer’s Disease: From Pathologic to Physiologic Biomarkers - p. 329 15. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias - p. 351 16. Novel Phenotypes Detectable with PET in Mood Disorders: Elevated Monoamine Oxidase A and Translocator Protein Level - p. 361
